These guidelines, produced by the National Institute for Health and Care Excellence (NICE), set out new recommendations for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within the NHS in England. Update information October 2018: Recommendations 1.8.13 to 1.8.17 were replaced by NICE’s guideline on venous thromboembolism in…
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
The Bone group of the IMWG present recommendations for the use of whole body low-dose CT in patients with myeloma and other plasma cell disorders, as an imaging method for assessing bone disease in these patients.
Pain is one of the most common and debilitating symptoms of progressive myeloma. This guidance written by NICE outlines safe use of opioids for adults with advanced disease.
The IMWG report on the newly developed revised version of the International Staging System (R-ISS) which incorporates chromosomal abnormalities to develop a more powerful staging system for stratifying myeloma patients.
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
In this guidance NICE outlines recommendations for the use of erythropoiesis-stimulating agents for the treatment of anaemia in cancer patients undergoing chemotherapy.
This NICE guidance outlines recommendations for the prevention, identification and management of neutropenic sepsis in people with cancer.